PDL1 Regulation by P53 Via MiR-34

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2015 Nov 19

PMID 26577528

Citations 358

Authors

Maria Angelica Cortez

Cristina Ivan

David Valdecanas

Xiaohong Wang

Heidi J Peltier

Yuping Ye

Luiz Araujo

David P Carbone

Konstantin Shilo

Dipak K Giri

Kevin Kelnar

Desiree Martin

Ritsuko Komaki

Daniel R Gomez

Sunil Krishnan

George A Calin

Andreas G Bader

James W Welsh

Affiliations

Soon will be listed here.

Abstract

Background: Although clinical studies have shown promise for targeting PD1/PDL1 signaling in non-small cell lung cancer (NSCLC), the regulation of PDL1 expression is poorly understood. Here, we show that PDL1 is regulated by p53 via miR-34.

Methods: p53 wild-type and p53-deficient cell lines (p53(-/-) and p53(+/+) HCT116, p53-inducible H1299, and p53-knockdown H460) were used to determine if p53 regulates PDL1 via miR-34. PDL1 and miR-34a expression were analyzed in samples from patients with NSCLC and mutated p53 vs wild-type p53 tumors from The Cancer Genome Atlas for Lung Adenocarcinoma (TCGA LUAD). We confirmed that PDL1 is a direct target of miR-34 with western blotting and luciferase assays and used a p53(R172HΔ)g/+K-ras(LA1/+) syngeneic mouse model (n = 12) to deliver miR-34a-loaded liposomes (MRX34) plus radiotherapy (XRT) and assessed PDL1 expression and tumor-infiltrating lymphocytes (TILs). A two-sided t test was applied to compare the mean between different treatments.

Results: We found that p53 regulates PDL1 via miR-34, which directly binds to the PDL1 3' untranslated region in models of NSCLC (fold-change luciferase activity to control group, mean for miR-34a = 0.50, SD = 0.2, P < .001; mean for miR-34b = 0.52, SD = 0.2, P = .006; and mean for miR-34c = 0.59, SD = 0.14, and P = .006). Therapeutic delivery of MRX34, currently the subject of a phase I clinical trial, promoted TILs (mean of CD8 expression percentage of control group = 22.5%, SD = 1.9%; mean of CD8 expression percentage of MRX34 = 30.1%, SD = 3.7%, P = .016, n = 4) and reduced CD8(+)PD1(+) cells in vivo (mean of CD8/PD1 expression percentage of control group = 40.2%, SD = 6.2%; mean of CD8/PD1 expression percentage of MRX34 = 20.3%, SD = 5.1%, P = .001, n = 4). Further, MRX34 plus XRT increased CD8(+) cell numbers more than either therapy alone (mean of CD8 expression percentage of MRX34 plus XRT to control group = 44.2%, SD = 8.7%, P = .004, n = 4). Finally, miR-34a delivery reduced the numbers of radiation-induced macrophages (mean of F4-80 expression percentage of control group = 52.4%, SD = 1.7%; mean of F4-80 expression percentage of MRX34 = 40.1%, SD = 3.5%, P = .008, n = 4) and T-regulatory cells.

Conclusions: We identified a novel mechanism by which tumor immune evasion is regulated by p53/miR-34/PDL1 axis. Our results suggest that delivery of miRNAs with standard therapies, such as XRT, may represent a novel therapeutic approach for lung cancer.

Citing Articles

MicroRNAs in lung cancer: their role in tumor progression, biomarkers, diagnostic, prognostic, and therapeutic relevance.

Chatterjee M, Nag S, Gupta S, Mukherjee T, Shankar P, Parashar D Discov Oncol. 2025; 16(1):293.

PMID: 40067551 PMC: 11896959. DOI: 10.1007/s12672-025-02054-9.

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H NPJ Breast Cancer. 2025; 11(1):23.

PMID: 40055382 PMC: 11889191. DOI: 10.1038/s41523-025-00730-1.

New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation.

Bettinsoli V, Melzi G, Marchese I, Pantaleoni S, Passoni F, Corsini E Curr Res Toxicol. 2025; 8:100222.

PMID: 40027547 PMC: 11872130. DOI: 10.1016/j.crtox.2025.100222.

TP53 Deficiency in the Natural History of Prostate Cancer.

Ofner H, Kramer G, Shariat S, Hassler M Cancers (Basel). 2025; 17(4).

PMID: 40002239 PMC: 11853097. DOI: 10.3390/cancers17040645.

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers.

Strati A, Adamopoulos C, Kotsantis I, Psyrri A, Lianidou E, Papavassiliou A Int J Mol Sci. 2025; 26(3).

PMID: 39941003 PMC: 11818137. DOI: 10.3390/ijms26031235.

References

Swaminathan S, Suzuki K, Seddiki N, Kaplan W, Cowley M, Hood C . Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression. J Immunol. 2012; 188(12):6238-46. DOI: 10.4049/jimmunol.1101196. View

Nakamura S, Roth J, Mukhopadhyay T . Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol. 2000; 20(24):9391-8. PMC: 102195. DOI: 10.1128/MCB.20.24.9391-9398.2000. View

Park B, Yee C, Lee K . The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014; 15(1):927-43. PMC: 3907847. DOI: 10.3390/ijms15010927. View

Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H . Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003; 424(6948):516-23. DOI: 10.1038/nature01850. View

Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A . Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007; 6(13):1586-93. DOI: 10.4161/cc.6.13.4436. View

Wiggins J, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D . Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010; 70(14):5923-30. PMC: 2913706. DOI: 10.1158/0008-5472.CAN-10-0655. View

Mollereau B, Ma D . The p53 control of apoptosis and proliferation: lessons from Drosophila. Apoptosis. 2014; 19(10):1421-9. PMC: 4167030. DOI: 10.1007/s10495-014-1035-7. View

Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y . Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2014; 27(3):443-52. DOI: 10.1016/j.cellsig.2014.12.003. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

10.

Cortez M, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin G . Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014; 22(8):1494-1503. PMC: 4435581. DOI: 10.1038/mt.2014.79. View

11.

Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J . PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009; 21(9):1065-77. PMC: 2731790. DOI: 10.1093/intimm/dxp072. View

12.

Menendez D, Shatz M, Azzam K, Garantziotis S, Fessler M, Resnick M . The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet. 2011; 7(3):e1001360. PMC: 3069118. DOI: 10.1371/journal.pgen.1001360. View

13.

Stalder L, Heusermann W, Sokol L, Trojer D, Wirz J, Hean J . The rough endoplasmatic reticulum is a central nucleation site of siRNA-mediated RNA silencing. EMBO J. 2013; 32(8):1115-27. PMC: 3630355. DOI: 10.1038/emboj.2013.52. View

14.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

15.

Chang T, Wentzel E, Kent O, Ramachandran K, Mullendore M, Lee K . Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26(5):745-52. PMC: 1939978. DOI: 10.1016/j.molcel.2007.05.010. View

16.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B . Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006; 119(2):317-27. DOI: 10.1002/ijc.21775. View

17.

Chen D, Irving B, Hodi F . Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012; 18(24):6580-7. DOI: 10.1158/1078-0432.CCR-12-1362. View

18.

Chen L, Gibbons D, Goswami S, Cortez M, Ahn Y, Byers L . Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5:5241. PMC: 4212319. DOI: 10.1038/ncomms6241. View

19.

Bader A . miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 2012; 3:120. PMC: 3387671. DOI: 10.3389/fgene.2012.00120. View

20.

Zou W, Chen L . Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8(6):467-77. DOI: 10.1038/nri2326. View